202 related articles for article (PubMed ID: 17168718)
21. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
22. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
Capdevila J; Elez E; Macarulla T; Ramos FJ; Ruiz-Echarri M; Tabernero J
Cancer Treat Rev; 2009 Jun; 35(4):354-63. PubMed ID: 19269105
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
[TBL] [Abstract][Full Text] [Related]
24. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
25. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
26. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
27. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER.
Moradi-Kalbolandi S; Hosseinzade A; Salehi M; Merikhian P; Farahmand L
J Pharm Pharmacol; 2018 Jul; 70(7):841-854. PubMed ID: 29574771
[TBL] [Abstract][Full Text] [Related]
29. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
30. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
31. Growth factors and their receptors: new targets for prostate cancer therapy.
Barton J; Blackledge G; Wakeling A
Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
[TBL] [Abstract][Full Text] [Related]
32. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
33. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies targeting the epidermal growth factor receptor.
Bianco R; Daniele G; Ciardiello F; Tortora G
Curr Drug Targets; 2005 May; 6(3):275-87. PubMed ID: 15857288
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
36. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
38. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer.
Ray K; Ujvari B; Ramana V; Donald J
Cytokine Growth Factor Rev; 2018 Jun; 41():18-27. PubMed ID: 29680500
[TBL] [Abstract][Full Text] [Related]
39. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Nakamura H; Takamori S; Fujii T; Ono M; Yamana H; Kuwano M; Shirouzu K
Cancer Lett; 2005 Dec; 230(1):33-46. PubMed ID: 16253759
[TBL] [Abstract][Full Text] [Related]
40. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
